14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RMD vs EW: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RMD Overall Winner
6-Pillar Tally: RMD 4 – 2 EW
Matrix Metrics: RMD 6 – 4 EW
As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RMD carries a Unified Composite Score of 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin).
Competes within the Medical Instruments & Supplies value chain with $33.6B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment27.8% of Rev ($1.59B)
90D Engineering Disclosures0 Published
EW Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment49.2% of Rev ($3.28B)
90D Engineering Disclosures0 Published
Investor FAQ RMD vs EW Key Questions & Quantitative Answers
As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RMD carries a Unified Composite Score of 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin). Technically, RMD sits in a Markup phase (RSI 54.8, CONSOLIDATION options structure) and EW sits in a Markup phase (RSI 79.4, UNCLASSIFIED options structure).
EW leads the Growth & Scale pillar: RMD posts +5.9% YoY revenue growth and +23.2% YoY earnings growth on $5.73B TTM revenue (61.8% gross margin, 34.0% operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), RMD cumulative revenue shifted +116.5% while EW shifted +39.5%. In operating R&D and SG&A reinvestment, RMD deploys 27.8% of Rev ($1.59B) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.
RMD screens cheaper on headline valuation multiples. RMD trades at 19.8x Forward P/E, 21.8x Trailing P/E, 1.28x PEG, and 5.8x EV/Revenue (27.7% FCF margin), whereas EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RMD (26.4% ROE) versus EW (9.3% ROE) capital efficiency.
In options market volatility and institutional positioning, RMD carries 28.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.41β · 43% Vol realized risk). By comparison, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.